A Randomized, Single-Blind, Single-Dose, 3-Arm, Parallel Group Study to Determine the Pharmacokinetic Equivalence of ABP 980 and Trastuzumab (Herceptin '(Registered Trademark)' ) in Healthy Male Subjects

Trial Profile

A Randomized, Single-Blind, Single-Dose, 3-Arm, Parallel Group Study to Determine the Pharmacokinetic Equivalence of ABP 980 and Trastuzumab (Herceptin '(Registered Trademark)' ) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 14 Jul 2017 Status changed from not yet recruiting to completed.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 16 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top